- Home
- JVA vs PMCB Comparison
JVA vs PMCB Comparison
Compare JVA & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JVA
- PMCB
- Stock Information
- Founded
- JVA 1971
- PMCB 1996
- Country
- JVA United States
- PMCB United States
- Employees
- JVA N/A
- PMCB N/A
- Industry
- JVA Packaged Foods
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JVA Consumer Staples
- PMCB Health Care
- Exchange
- JVA Nasdaq
- PMCB Nasdaq
- Market Cap
- JVA 14.7M
- PMCB 15.8M
- IPO Year
- JVA 2005
- PMCB N/A
- Fundamental
- Price
- JVA $2.96
- PMCB $1.74
- Analyst Decision
- JVA
- PMCB
- Analyst Count
- JVA 0
- PMCB 0
- Target Price
- JVA N/A
- PMCB N/A
- AVG Volume (30 Days)
- JVA 173.3K
- PMCB 37.2K
- Earning Date
- JVA 10-11-2024
- PMCB 09-17-2024
- Dividend Yield
- JVA N/A
- PMCB N/A
- EPS Growth
- JVA N/A
- PMCB N/A
- EPS
- JVA 0.20
- PMCB 0.54
- Revenue
- JVA $76,111,698.00
- PMCB N/A
- Revenue This Year
- JVA N/A
- PMCB N/A
- Revenue Next Year
- JVA N/A
- PMCB N/A
- P/E Ratio
- JVA $15.39
- PMCB $3.33
- Revenue Growth
- JVA 17.27
- PMCB N/A
- 52 Week Low
- JVA $0.67
- PMCB $1.39
- 52 Week High
- JVA $3.88
- PMCB $2.58
- Technical
- Relative Strength Index (RSI)
- JVA 55.68
- PMCB 47.56
- Support Level
- JVA $3.00
- PMCB $1.64
- Resistance Level
- JVA $3.74
- PMCB $2.06
- Average True Range (ATR)
- JVA 0.35
- PMCB 0.29
- MACD
- JVA -0.03
- PMCB 0.00
- Stochastic Oscillator
- JVA 43.59
- PMCB 33.82
About JVA Coffee Holding Co. Inc.
Coffee Holding Co Inc is engaged in the business of wholesale coffee operations, including manufacturing, roasting, packaging, marketing and distributing roasted and blended coffees for private labeled accounts and its own brands, and it sells green coffee. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada and certain countries in Asia.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.